drugset / Trial / NCT04504812
A Sequenced Strategy for Improving Outcomes in People With Knee Osteoarthritis Pain
Phase 3
Completed
1937 enrolled
Johns Hopkins University
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · collabPacira Pharmaceuticals, Inc · collab
RandomizedSequentialSingle-blindTreatment
Summary
There is an urgent public health need to reduce reliance on opioids for effective long-term pain management, particularly in knee osteoarthritis (KOA). This effectiveness trial will compare commonly recommended treatments to reduce pain and functional limitations in KOA.These results will lead to improved patient selection for treatment and inform evidence based guidelines by offering well-tested, effective, non-surgical alternatives.
Timeline
- Start
- 2021-02-01
- Primary completion
- 2025-04-08
- Completion
- 2025-04-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bupivacaine | Other / unclassified | 2 ml | Other |
| Comparator | Duloxetine | Small molecule | 20 mg | — |
| Comparator | Duloxetine | Small molecule | 30 mg | — |
| Subject | Hyaluronic Acid | Other / unclassified | — | Other |
| Subject | Methylprednisolone | Other / unclassified | 1 ml | Other |